Literature DB >> 8192473

Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.

N Mobarakai1, J M Quale, D Landman.   

Abstract

Multidrug-resistant Enterococcus faecium has emerged as a serious pathogen for which no effective therapy has been established. In this report, we describe the activities of two peptide antibiotics, ramoplanin and daptomycin, against 15 isolates of E. faecium resistant to vancomycin, ampicillin, and aminoglycosides using time-kill experiments. Both antibiotics were rapidly bactericidal when tested in broth; however, the addition of 50% serum resulted in significant regrowth. The combination of ampicillin with either ramoplanin or daptomycin largely prevented this regrowth. These peptide antibiotics showed good activity against these pathogens. While the development of daptomycin has been halted, ramoplanin may hold promise for the therapy of multidrug-resistant E. faecium, especially when combined with ampicillin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8192473      PMCID: PMC284464          DOI: 10.1128/AAC.38.2.385

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Identification of Enterococcus species isolated from human infections by a conventional test scheme.

Authors:  R R Facklam; M D Collins
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

2.  Suboptimal effect of daptomycin in the treatment of bacteremias.

Authors:  M W Garrison; J C Rotschafer; K B Crossley
Journal:  South Med J       Date:  1989-11       Impact factor: 0.954

3.  Effect of protein binding of daptomycin on MIC and antibacterial activity.

Authors:  B L Lee; M Sachdeva; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.

Authors:  A Bartoloni; M G Colao; A Orsi; R Dei; E Giganti; F Parenti
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

5.  Inhibition of membrane potential-dependent amino acid transport by daptomycin.

Authors:  N E Allen; W E Alborn; J N Hobbs
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

6.  Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci.

Authors:  S Handwerger; D C Perlman; D Altarac; V McAuliffe
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

7.  Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci.

Authors:  R Leclercq; E Bingen; Q H Su; N Lambert-Zechovski; P Courvalin; J Duval
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

8.  Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution.

Authors:  M L Grayson; G M Eliopoulos; C B Wennersten; K L Ruoff; P C De Girolami; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

9.  Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

Authors:  E Bingen; N Lambert-Zechovsky; R Leclercq; C Doit; P Mariani-Kurkdjian
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

10.  Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model.

Authors:  M W Garrison; K Vance-Bryan; T A Larson; J P Toscano; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

View more
  16 in total

1.  Molecular characterization of vancomycin-resistant Enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin.

Authors:  L R Baden; I A Critchley; D F Sahm; W So; M Gedde; S Porter; R C Moellering; G Eliopoulos
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

Review 2.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  In vitro activities of a new lipopeptide, HMR 1043, against susceptible and resistant gram-positive isolates.

Authors:  Pascale Bemer; Marie-Emmanuelle Juvin; Andre Bryskier; Henri Drugeon
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

5.  Pharmacological properties of NAI-603, a well-tolerated semisynthetic derivative of ramoplanin.

Authors:  Daniela Jabes; Cristina Brunati; GianPaolo Candiani; Simona Riva; Gabriella Romanó; Sonia Maffioli; Rosaria Rossi; Matteo Simone; Eleonora Gaspari; Stefano Donadio
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

6.  Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.

Authors:  R C Mercier; H H Houlihan; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.

Authors:  George Sakoulas; Arnold S Bayer; Joseph Pogliano; Brian T Tsuji; Soo-Jin Yang; Nagendra N Mishra; Victor Nizet; Michael R Yeaman; Pamela A Moise
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

8.  Daptomycin dose-effect relationship against resistant gram-positive organisms.

Authors:  Raymond Cha; Richard G Grucz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

9.  In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Authors:  Janet A Hindler; Annie Wong-Beringer; Carmen L Charlton; Shelley A Miller; Theodoros Kelesidis; Marissa Carvalho; George Sakoulas; Poochit Nonejuie; Joseph Pogliano; Victor Nizet; Romney Humphries
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

10.  In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods.

Authors:  James H Jorgensen; Sharon A Crawford; Cynthia C Kelly; Jan E Patterson
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.